The natural course of lung function decline in asbestos exposed subjects with pleural plaques and asbestosis.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
Historique:
received: 28 10 2018
revised: 10 06 2019
accepted: 11 06 2019
pubmed: 22 6 2019
medline: 5 8 2020
entrez: 22 6 2019
Statut: ppublish

Résumé

While there is a good knowledge of the natural course of lung function in interstitial lung diseases (ILD) like idiopathic lung fibrosis (IPF), many ambiguities remain in patients with asbestosis. Therefore, we evaluated the change in lung function in asbestos exposed subjects with pleural plaques and asbestosis and analysed corresponding morphology of computer tomography of the thorax. 93 asbestos exposed subjects with pleural plaques and asbestosis were analysed retrospectively at the Klinikum Bergmannsheil of the Ruhr-University of Bochum. Parameters of lung function were obtained at least twice and annual changes of FVC, TLC and DLCOsb were calculated. In addition, we assessed the predominant pattern in high-resolution computer tomography of the thorax (HRCT) and differentiated three phenotypes: p (pleural) -type, f (fibrosis) -type and m (mixed) -type. FU data are available in 56/93 (60.2%) patients. The annual deterioration (Mean ± SEM) of FVC is -31.46 ± 17.34 ml, of TLC -55.55 ± 25.67 ml, of DLCOsb -0.38 ± 0.07 mmol/min/kPa and of DLCOva -0.05 ± 0.01 mmol/min/kPa/L. A categorical change of FVC > -100 ml was found in 12/56 (21.4%) and 18/56 (32.1%) patients showed an annual loss of TLC > -100 ml. The greatest annual decline of FVC was observed in patients with the fibrotic phenotype on HRCT (-76.76 ± 66.43 ml) and the mixed phenotype (-81.52 ± 24.79 ml), while the pleural phenotype was less affected (-10.52 ± 25.07 ml). More than 20% of our cohort have a progressive disease with an annual loss of FVC > -100 ml. Patients with the fibrotic-phenotype or mixed-phenotype on HRCT are particularly at risk.

Identifiants

pubmed: 31226624
pii: S0954-6111(19)30203-3
doi: 10.1016/j.rmed.2019.06.013
pii:
doi:

Substances chimiques

Asbestos 1332-21-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

82-85

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

M Barnikel (M)

Department of Internal Medicine V, Ludwig-Maximilians University Munich, LMU, Member of the German Center for Lung Research, Germany.

P M Million (PM)

Abteilung für Plastische und Handchirurgie, Kliniken Landkreis Diepholz, Bassum, Germany.

H Knoop (H)

Gemeinschaftspraxis für Innere Medizin und Pneumologie, Allergologie, Schlafmedizin, Gelsenkirchen, Germany.

J Behr (J)

Department of Internal Medicine V, Ludwig-Maximilians University Munich, LMU, Member of the German Center for Lung Research, Germany; Asklepios Fachkliniken München-Gauting, Member of German Center for Lung Research, Germany. Electronic address: juergen.behr@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH